Australia markets closed

    -83.90 (-1.04%)
  • ASX 200

    -84.20 (-1.08%)

    +0.0022 (+0.33%)
  • OIL

    +0.93 (+1.21%)
  • GOLD

    -2.00 (-0.09%)
  • Bitcoin AUD

    +2,410.46 (+2.38%)
  • CMC Crypto 200

    -27.29 (-1.86%)

    +0.0005 (+0.08%)

    -0.0005 (-0.04%)
  • NZX 50

    -26.09 (-0.22%)

    +184.96 (+0.99%)
  • FTSE

    -21.64 (-0.26%)
  • Dow Jones

    +4.33 (+0.01%)
  • DAX

    +2.05 (+0.01%)
  • Hang Seng

    -259.77 (-1.38%)
  • NIKKEI 225

    -457.11 (-1.17%)

Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript

Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript March 14, 2024

Evoke Pharma, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were $-0.5. Evoke Pharma, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good afternoon, and welcome to the Evoke Pharma Fourth Quarter and Full-Year 2023 Earnings Conference Call. Currently, all callers have been placed in a listen-only mode. [Operator Instructions] Please be advised that today’s call is being recorded. I will now turn the call over to Daniel Kontoh-Boateng. Please go ahead, sir.

Daniel Kontoh-Boateng: Good afternoon, and thank you for participating in Evoke Pharma's conference call and webcast today. With me today are Dave Gonyer, Evoke's Chief Executive Officer; Chris Quesenberry, GIMOTI's Chief Commercial Officer from Eversana; and Matt D'Onofrio, Evoke's President and Chief Operating Officer. By now, you should have a copy of the press release we issued earlier. If not, it is available on the Investor Relations page of our website at We encourage everyone to read today's press release as well as Evoke’s annual report on Form 10-K, which is now filed with the SEC. The company's Form 10-K and earnings release are also available on Evoke's website. Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act.


We caution listeners that, during this call, management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Evoke's press releases and SEC filings, including its annual report on Form 10-K and subsequent filings. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast. Evoke undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call and webcast.

A clinical researcher in a lab examining a new biopharmaceutical product.

With that, I would now like to turn the call over to David Gonyer. Dave?

David Gonyer: Thank you, Daniel, and thanks, everyone, for joining the call this afternoon. As was described in today's press release, 2023 marks a milestone in Evoke's journey, not just commercially, but also in fulfilling our core mission, which is ensuring GIMOTI is within reach for every patient who needs it. Let me tell you why this core mission is so important. It's because it's about the patient and their experiences that can and will fuel the progress to help us fuel the progress as an organization. A testament to our efforts comes from the countless positive stories we've been told from health care providers, patients and our own sales representatives who hear and tell us some amazing patient success stories on a daily basis.

See also 25 Poorest States in the US in 2024 and 20 Cities Where Home Prices Are Falling Most in the US.

To continue reading the Q&A session, please click here.